These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24759791)

  • 21. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
    Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
    BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
    Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?
    Quinn GR; Singer DE; Chang Y; Go AS; Borowsky LH; Fang MC
    Am J Cardiol; 2016 Sep; 118(5):697-9. PubMed ID: 27394408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Lip GYH; Mauri L; Montalescot G; Ozkor M; Vardas P; Steg PG; Bhatt DL; Hohnloser SH; Miede C; Nordaby M; Brueckmann M; Kreuzer J; Kimura T; Oldgren J; Ten Berg JM; Cannon CP
    Am Heart J; 2019 Jun; 212():13-22. PubMed ID: 30928824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation. Subanalysis of the J-RHYTHM Registry.
    Inoue H; Atarashi H; Okumura K; Yamashita T; Kumagai N; Origasa H
    Circ J; 2014; 78(10):2388-93. PubMed ID: 25099606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
    Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry).
    Mori N; Sotomi Y; Hirata A; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Oct; 124(7):1044-1048. PubMed ID: 31353002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Lip GY; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
    Stroke; 2016 Oct; 47(10):2462-9. PubMed ID: 27625386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation.
    Chau KH; Scherzer R; Grunfeld C; Hsue PY; Shlipak MG
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):90-97. PubMed ID: 28797024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants.
    Wattanaruengchai P; Nathisuwan S; Karaketklang K; Wongcharoen W; Phrommintikul A; Lip GYH
    Br J Clin Pharmacol; 2022 May; 88(5):2203-2212. PubMed ID: 34783372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
    Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.